JP2008516991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516991A5 JP2008516991A5 JP2007537071A JP2007537071A JP2008516991A5 JP 2008516991 A5 JP2008516991 A5 JP 2008516991A5 JP 2007537071 A JP2007537071 A JP 2007537071A JP 2007537071 A JP2007537071 A JP 2007537071A JP 2008516991 A5 JP2008516991 A5 JP 2008516991A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antisense compound
- administered
- animal
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (18)
- 呼吸疾患又は気道過敏症、好酸球増加症、好中球増加症、白血球又は粘液の過剰生産及び／又はインテグリンα４の発現に関連する病態を有する動物を治療及び／又は予防するための医薬の製造におけるインテグリンα４をコードする核酸分子を標的とするアンチセンス化合物の使用であって、前記医薬が、前記動物の体重１ｋｇ当たり０．００１から５００μｇの用量レベルで投与される使用。
- 前記医薬が局所投与される、請求項１に記載の使用。
- 前記医薬が１日に１回以下しか投与されない、請求項１又は２に記載の使用。
- 前記アンチセンス化合物が、前記個々の動物の体重１ｋｇ当たり０．００５から２００μｇのレベルで当該動物に投与される、請求項１から３のいずれか一項に記載の使用。
- 前記アンチセンス化合物が、前記個々の動物の体重１ｋｇ当たり０．５から５０μｇのレベルで当該動物に投与される、請求項４に記載の使用。
- 前記アンチセンス化合物が、前記個々の動物の体重１ｋｇ当たり５μｇ以下の用量で投与される、請求項１から５のいずれか一項に記載の使用。
- 前記アンチセンス化合物が、前記個々の動物の体重１ｋｇ当たり１μｇ以下の用量で投与される、請求項６に記載の使用。
- 前記化合物が、吸入又は吹送を介して局所投与される、請求項１から７のいずれか一項に記載の使用。
- 前記組成物が、肺内、鼻内又は気管内に投与される、請求項１から７のいずれか一項に記載の使用。
- 前記組成物が、定量吸入器（ＭＤＩ）、噴霧器、又は粉末吸入器（ＤＰＩ）を介して投与される、請求項９に記載の使用。
- 前記疾患又は病態が、喘息、嚢胞性線維症、アルファ１−アンチトリプシン欠損症、慢性閉塞性肺疾患、慢性気管支炎及び鼻炎から選択される、請求項１から１０のいずれか一項に記載の使用。
- 前記疾患又は病態が喘息である、請求項１１に記載の使用。
- インテグリンα４をコードする核酸分子を標的とするアンチセンス化合物を含む組成物、及び、動物の体重１ｋｇ当たり０．００１から５００μｇの前記アンチセンス化合物という用量レベルで前記組成物を吸入又は吹送によって投与することのできる装置を含むキット。
- インテグリンα４をコードする核酸分子を標的とするアンチセンス化合物を含む組成物、及び、治療される動物の体重１ｋｇ当たり０．００１から５００μｇの前記アンチセンス化合物という用量範囲で前記組成物を投与する指示書を含むキット。
- 前記アンチセンス化合物が、アンチセンスオリゴヌクレオチドを含む、請求項１から１２のいずれか一項に記載の使用。
- 前記アンチセンス化合物が、配列番号８１、１１７、１２０、１２１、１２２、１２８、１３０、１３１、１３２、１３６、１３７、１３８、１４１、１４９、１５０、１５９、１６０、１６１、１６７及び１６８から選択されるアンチセンスオリゴヌクレオチドを含む、請求項１５に記載の使用。
- 前記アンチセンス化合物が、配列番号８１のアンチセンスオリゴヌクレオチドを含む、請求項１６に記載の使用。
- 前記アンチセンス化合物が、インテグリンα４の発現を少なくとも５０％阻害する、請求項１から１２及び１５から１７のいずれか一項に記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62079204P | 2004-10-20 | 2004-10-20 | |
| US64882005P | 2005-01-31 | 2005-01-31 | |
| PCT/AU2005/001634 WO2006086821A1 (en) | 2004-10-20 | 2005-10-20 | ANTISENS MODULATION OF INTEGRIN α4 EXPRESSION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008516991A JP2008516991A (ja) | 2008-05-22 |
| JP2008516991A5 true JP2008516991A5 (ja) | 2008-12-04 |
Family
ID=36916094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537071A Pending JP2008516991A (ja) | 2004-10-20 | 2005-10-20 | インテグリンα４発現のアンチセンス調節 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8765700B2 (ja) |
| EP (1) | EP1809302B1 (ja) |
| JP (1) | JP2008516991A (ja) |
| AU (1) | AU2005327506B2 (ja) |
| CA (1) | CA2584614A1 (ja) |
| DK (1) | DK1809302T3 (ja) |
| ES (1) | ES2392449T3 (ja) |
| NZ (1) | NZ554277A (ja) |
| WO (1) | WO2006086821A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010008474A2 (en) * | 2008-06-23 | 2010-01-21 | Teva Pharmaceutical Industries, Ltd. | Methods for treating multiple sclerosis using antisense oligonucleotides |
| US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| WO2012034194A1 (en) * | 2010-09-17 | 2012-03-22 | Antisense Therapeutics Ltd | Method for mobilizing stem and/or progenitor cells |
| WO2013142514A1 (en) * | 2012-03-19 | 2013-09-26 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
| CN104272317B (zh) * | 2012-06-01 | 2017-09-15 | 英特尔公司 | 在更安全的执行环境中标识并执行多个指令的子集 |
| EP3294889B1 (en) * | 2015-05-11 | 2021-01-06 | Murdoch University | Multiple sclerosis treatment |
| WO2017075670A1 (en) | 2015-11-05 | 2017-05-11 | Children's Hospital Los Angeles | "mobilizing leukemia cells" |
| EP3568482A4 (en) | 2017-01-10 | 2020-12-16 | Arrowhead Pharmaceuticals, Inc. | ALPHA-1 ANTITRYPSIN (AAT) RNA INTERFERENCE (RNA) AGENTS, COMPOSITIONS CONTAINING THEM, AND PROCEDURES FOR USE THEREOF |
| KR20210018820A (ko) * | 2018-05-04 | 2021-02-18 | 안티센스 테라퓨틱스 엘티디 | 치료 용도 및 방법 |
| MX2021015003A (es) * | 2019-06-06 | 2022-01-24 | Arrowhead Pharmaceuticals Inc | Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd). |
| WO2023039643A1 (en) * | 2021-09-20 | 2023-03-23 | Antisense Therapeutics Ltd | Methods and kits therefor |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4309406A (en) | 1979-07-10 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309404A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| EP0260032B1 (en) | 1986-09-08 | 1994-01-26 | Ajinomoto Co., Inc. | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers |
| DE3855864T2 (de) | 1987-11-30 | 1997-09-25 | Univ Iowa Res Found | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene |
| US5403711A (en) | 1987-11-30 | 1995-04-04 | University Of Iowa Research Foundation | Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| DE69034150T2 (de) | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
| US5859221A (en) | 1990-01-11 | 1999-01-12 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5623065A (en) | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
| US5955589A (en) | 1991-12-24 | 1999-09-21 | Isis Pharmaceuticals Inc. | Gapped 2' modified oligonucleotides |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| DE69032425T2 (de) | 1990-05-11 | 1998-11-26 | Microprobe Corp | Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden |
| DE59208572D1 (de) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| EP0691968B1 (en) | 1993-03-30 | 1997-07-16 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
| DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
| FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
| WO1995015972A1 (en) | 1993-12-09 | 1995-06-15 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5696248A (en) | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
| US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| US6083923A (en) | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
| US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
| DE19860642A1 (de) * | 1998-12-29 | 2000-07-06 | Deutsches Krebsforsch | Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen |
| AU4031700A (en) * | 1999-04-06 | 2000-11-02 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion |
| EP1859040A2 (en) * | 2005-02-25 | 2007-11-28 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to il-4r alpha |
-
2005
- 2005-10-20 AU AU2005327506A patent/AU2005327506B2/en not_active Ceased
- 2005-10-20 ES ES05857292T patent/ES2392449T3/es active Active
- 2005-10-20 DK DK05857292.6T patent/DK1809302T3/da active
- 2005-10-20 US US11/666,001 patent/US8765700B2/en not_active Expired - Fee Related
- 2005-10-20 CA CA002584614A patent/CA2584614A1/en not_active Abandoned
- 2005-10-20 NZ NZ554277A patent/NZ554277A/en not_active IP Right Cessation
- 2005-10-20 EP EP05857292A patent/EP1809302B1/en not_active Not-in-force
- 2005-10-20 WO PCT/AU2005/001634 patent/WO2006086821A1/en active Application Filing
- 2005-10-20 JP JP2007537071A patent/JP2008516991A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516991A5 (ja) | ||
| AU2002351181B2 (en) | Methods and compositions for treating lesions of the respiratory epithelium | |
| TWI758617B (zh) | 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途 | |
| JP2009529539A (ja) | 呼吸器障害を治療するための方法および組成物 | |
| US20090227511A1 (en) | Methods and compositions for treating lesions of the respiratory epithelium | |
| JP2010522212A5 (ja) | ||
| EP0946201A1 (en) | Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation | |
| CA2558212A1 (en) | Interferon-beta for anti-virus therapy for respiratory diseases | |
| WO2007109118A3 (en) | RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS | |
| WO1998023294A9 (en) | Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation | |
| CN102186458A (zh) | 治疗慢性阻塞性肺病及其它肺疾病的方法 | |
| Schüepp et al. | Deposition of aerosols in infants and children | |
| WO2005063777A8 (en) | Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation | |
| Siobal | Aerosolized prostacyclins | |
| JP2004532900A5 (ja) | ||
| Dolovich | Aerosol delivery to children: what to use, how to choose | |
| RU2008102655A (ru) | Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути | |
| US11642372B2 (en) | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses | |
| Dubus et al. | Electrostatic charge on spacer devices and salbutamol response in young children | |
| JP2009506029A5 (ja) | ||
| JP2008543926A5 (ja) | ||
| Everard et al. | In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system. | |
| TW201016215A (en) | Compositions and uses of antiviral active pharmaceutical agents | |
| WO2007046113A3 (en) | Novel pharmaceutical composition comprising alkaloid and process thereof | |
| Hansen et al. | Domiciliary nebulized terbutaline in severe chronic airways obstruction |